023910.KQ Daihan Pharmaceutical Co.Ltd

Healthcare Oil, Gas & Consumable Fuels KOSDAQ
24,750 KRW
Close of Oct 31, 2026
24,000 31,200
Market cap
KRW 146B
P/E
5.3x
P/B
0.47x
ROE
8.9%
Dividend yield
3.57%
Fundamental score
3.2/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 023910.KQ undervalued?

Graham number
Price24,750
Graham value73,916
Discount66.5%

023910.KQ trades 66.5% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Daihan Pharmaceutical Co.Ltd fundamental analysis

16 of 22 checks passed

ROE 0/2

Low return on equity (8.9%), below 10%.

ROA 1/1

Return on assets (7.6%) is above the industry median (1.4%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-18.1%) is not above the 5-year average (10.2% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-18.1%) is below the industry median (1.8%).

Revenue Growth 1/2

Revenue grew 4.2% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 19,901.4x against interest expense, well covered.

PE vs Market 1/1

PE (5.3x) is below the market median (11.3x).

PE vs Industry 1/1

PE (5.3x) is below the industry median (11.4x).

PBV 1/1

Price to book (0.5x) is below the industry median (0.9x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 2.5, limit 22.5).

PEG 1/1

PEG on 5-year earnings growth is 0.53, growth is cheap.

Dividend Yield 1/2

Dividend yield (3.6%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 11 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 18.8%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Daihan Pharmaceutical Co.Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Daihan Pharmaceutical Co.Ltd

Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.

Full company profile